Eli Lilly (LLY) Q2 2026 Earnings Overview: GLP-1 Sales and Raised Guidance Drive a 4.86% Rally
Eli Lilly's Q2 2026 results materially exceeded consensus, with revenue up 48% YoY and non-GAAP EPS well above estimates, driven by tirzepatide (Mounjaro/Zepbound) contributing ~65% of sales. Management raised full-year revenue guidance and improved margin expectations, supporting the post-earnings equity repricing despite acquisition-related charges and ongoing pricing pressure. The update reinforces confidence in GLP-1 demand while keeping execution and cost headwinds in focus.
AI Insight · NCSKLLY2USD/USDTAI Insight
▲ Bullish
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Eli Lilly reported Q2 2026 revenue of $22.97 billion, up 48% year over year, and non-GAAP EPS of $8.38, ahead of LSEG estimates. This earnings analysis reviews GLP-1 product growth, raised 2026 guidance, LLY’s 4.86% post-results rally and the technical levels shaping the August outlook.